XORTX Confirms Effective Date of Share Consolidation
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on treatments for gout and kidney diseases, has received all necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange to implement a share consolidation on a 1-for-5 basis, effective April 6, 2026. The company is advancing several clinical and preclinic…